Verona Pharma plc is a clinical-stage biopharmaceutical company focusing on the development of therapeutics for respiratory conditions with unmet medical needs. The company's primary objective is to c... Verona Pharma plc is a clinical-stage biopharmaceutical company focusing on the development of therapeutics for respiratory conditions with unmet medical needs. The company's primary objective is to create innovative drugs for diseases such as chronic obstructive pulmonary disease (COPD) and asthma, which significantly affect patients worldwide. A key asset in Verona Pharma's portfolio is ensifentrine, a dual inhibitor of the enzymes phosphodiesterase 3 and 4, designed to deliver bronchodilation and anti-inflammatory effects through inhalation. This novel mechanism is intended to address both the symptoms and underlying inflammation associated with respiratory disorders. Verona Pharma plc plays a crucial role in the healthcare sector, particularly in the specialty pharmaceuticals market, by exploring therapies that could offer alternative or supplementary options to existing treatment regimes. With its commitment to advancing respiratory medicine, Verona Pharma is positioned as a pivotal player in improving patient outcomes for chronic respiratory diseases.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

No Greenhouse Gas (GHG) Emissions data disclosed by Verona Pharma

We reviewed Verona Pharma's website and available disclosure materials for the 2023 reporting period and did not identify any reported Greenhouse Gas (GHG) Emissions data.

If you would like us to review newly published materials or reassess the most recent disclosures, you can submit a data update request.

Would you like us to review Verona Pharma's data?

Start your 30-day free trial to request a data review for Verona Pharma.

Start Free Trial

Legal Center Contact Us